Atrium Health Levine Cancer | Strategic Alliance Partners

September 30, 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

September 27, 2021

Jubilee Brown, MD, contextualizes updates in endometrial cancer and cervical cancer, frontline and second-line maintenance, and novel immune-oncology combination strategies in ovarian cancer.

August 31, 2021

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

July 07, 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.

July 01, 2021

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

June 02, 2021

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.

May 20, 2021

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

May 18, 2021

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

May 10, 2021

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

April 30, 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

April 27, 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

April 26, 2021

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

April 23, 2021

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

April 22, 2021

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

April 20, 2021

Matthew C. Ward, MD, discusses the debate over adjuvant radiation therapy in prostate cancer.

April 20, 2021

Saad Z. Usmani, MD, FACP, discusses treatment considerations for patients with multiple myeloma who are in their second relapse or beyond.

April 16, 2021

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

April 16, 2021

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

April 15, 2021

Saad Z. Usmani, MD, FACP, discusses the rapidly changing cellular therapy paradigm in relapsed/refractory multiple myeloma.

April 05, 2021

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.